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Gem/Bu/Mel BEAM Bu/Mel P valueN 89 83 37Age, median (range) 32 (19-61) 36 (17-67) 36 (20-63) 0.7% PIF 64 46 32 0.002% CR1 <6 mo 81 73 86 0.2% prior xRT 27 30 30 0.9% relapse within prior xRT field 12 9 11 0.8% >1 relapses 43 26 22 0.02% bulky tumor at relapse 37 18 22 0.009% B symptoms at relapse 15 14 8 0.6% extranodal disease at relapse 51 30 32 0.01% PET+ at HDC 52 28 27 0.001% PD at HDC 26 6 3 <0.0001The overall and CR rates were: Gem/Bu/Mel: 93% and 81%;
BEAM: 93% and 66%; Bu/Mel: both 64%. Despite its worse prog-
nostic features Gem/Bu/Mel pts had improved EFS (63% v 42% v
38%, P 5 0.002) and OS (85% v 63% v 62%, P 5 0.02) compared
to BEAM or Bu/Mel. Gem/Bu/Mel was superior in both PET-and
PET+ subsets. Cox regressionmodels identified the use of a regimen
other than GemBuMel [risk ratio 2.1 (95% CI, 1.3-3.5), P5 0.002],
PET+ tumors at HDC [RR 1.9 (1.2-3.1), P 5 0.002] and .1 prior
relapse [RR 1.8 (1.1-2.9), P 5 0.01] as independent adverse predic-
tors of EFS.
Conclusions:Despite its markedly worse prognostic features, refrac-
tory HL pts treated with the novel regimen Gem/Bu/Mel show supe-
rior outcome than contemporaneous pts receiving BEAM or Bu/Mel.
A randomized trial of Gem/Bu/Mel vs BEAM is warranted.
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HIGHER MELPHALAN EXPOSURE IS ASSOCIATED WITH IMPROVED
OVERALL SURVIVAL FOR MYELOMA PATIENTS UNDERGOING AUTOLO-
GOUS TRANSPLANT
Shaw, P.J.1,2, Nath, C.E.1, Nivison-Smith, I.3, Joshua, D.E.4,2,
Kerridge, I.H.5,2, Presgrave, P.6, Tiley, C.R.7, Kwan, Y.L.8,
Trotman, J.8,2 1Children’s Hospital at Westmead, Sydney, NSW, Aus-
tralia; 2University of Sydney; 3St Vincent’s Hospital, Sydney; 4Royal
Prince Alfred Hospital, Sydney; 5Royal North Shore Hospital, Sydney;
6Wollongong Hospital,Wollongong; 7Gosford Hospital, Gosford; 8Concord
Hospital, Sydney
Introduction and Aims:High dose melphalan (HDM) followed by
autologous stem cell transplantation (ASCT) has a central role in the
treatment ofmyeloma.Wehave already shown that patients given the
same dose ofHDMare exposed to a 5 fold variation in total exposure,
as measured by area-under-the-concentration-versus-time curve
(AUC) (1). It may be possible to improve outcomes by modifying
the individual patient dose to optimize their exposure to melphalan.
The aimof this studywas to investigate if exposure toHDMwas a sig-
nificant determinant of outcome in myeloma patients.
Methods:This study included myeloma patients undergoing HDM
at six hematology centres, from 2004-2010. Melphalan concentra-
tions were measured in 6-11 plasma samples collected after a median
dose of 192mg/m2 (range: 136–450 mg). This data was used to de-
velop a population pharmacokinetic model for melphalan (1) and
to determine total exposure to melphalan (AUC) for each patient.
In this pharmacodynamic analysis, we report the relationship be-
tween exposure to various levels of melphalan and clinical outcome.
Transplant toxicities were recorded using the Common Toxicity
Criteria. Factors affecting transplant toxicity and disease outcomes
were analysed by Cox regression analysis.
Results: A total of 115 patients (66 males, 49 females) aged 35-73
years (median 58 years) were studied, with a median follow-up of
3.1 years. Myeloma type was IgG (n 5 72), IgA (n 5 26), biclonal
(n 5 1), Light chain only (n 5 14) and non-secretory (n 5 2). Mel-
phalan AUC ranged from 4.9- 24.6 mg/L.h, median 12.85 mg/L.h.
Risk factors for mucositis of$Grade 3 were higher melphalan expo-
sure (HR1.17, p5 0.03) and higher pre-transplant b2-microglobulin
(HR 4.39, p5 0.007). Patients with AUC above the median were as-
sociated with the following: (1) improved Time to Progression
(TTP), HR 0.56, p\0.02, (2) improved overall survival (OS) at
both 2 years (91% versus 78%) and 4 years (82% versus 55%), HR0.35, (p 5 0.006). Progression free survival was not statistically sig-
nificant, HR 0.64, (p 5 0.08).
Conclusions: Detailed pharmacokinetic data following administra-
tion of HDM confirms that high exposure is associated with more
mucositis, but an improved outcome, as measured by TTP and
OS.These results suggest targeting a higher AUC is warranted in pa-
tients receiving HDM.
(1) Nath CE et al. Br.J.Clin.Pharmacol. 2010; 69: 484 – 497.
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INCIDENCE OF CARDIAC ARRHYTHMIAS DURING AUTOLOGOUS PERIPH-
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Background: Arrhythmias, especially supraventricular arrhythmias
(SVA), often complicate autologous stem cell transplantation
(ASCT).While easily treatable, they result in prolongation of hospi-
tal stay and increased rate of intensive care admissions. We under-
took this study to determine the incidence and risk factors for
cardiac arrhythmias during ASCT.
Methods:We examined the medical records of 983 patients who un-
derwent ASCT for various hematological malignancies between Aug
2006 andDec 2010.The underlying disease included plasma cell disor-
ders in 573 (58%)patients and lymphomaor leukemia in the remaining.
Results: The median age was 58 years (range; 19-77); 603 (61%)
were male. Overall, 92 (9.4%) patients developed a SVA following
ASCT, at a median of 9 days post transplant (range; 0, 18). Atrial fi-
brillation was most common and was seen in 71 (7%) patients, fol-
lowed by atrial flutter, supraventricular tachycardia and multifocal
tachycardia in 12 (1%), 8 (1%) and 1 (\1%) patients respectively.
The rhythm had normalized in 81 (88%) patients at the time of dis-
missal post transplant, with a median duration of arrhythmia of\1
day (range; \1 to 17 days). We then examined various pre and
peri-transplant clinical and laboratory parameters to identify risk fac-
tors for SVA. In a univariate analysis, older age, presence of supraven-
tricular complexes or AV conduction delays on pre-transplant ECG,
presence of any valvular abnormality, increased atrial size, any prior
history of arrhythmia, or being on a beta blocker or an antiarrhythmic
agent, all increased the risk. In a multivariate analysis, only age. 63
years, presence of supraventricular complexes or AV conduction de-
lays on pre-transplant ECG, and history of any prior arrhythmia in-
creased the risk of arrhythmia during transplant. Among the patients
with age . 63 years, presence of supraventricular complexes or AV
conduction delays on pre-transplant ECG, and history of any prior
arrhythmia, 20%, 26% and 23% respectively developed an arrhyth-
mia compared to 4%, 8% and 8% among those without the risk fac-
tors, respectively (P\ 0.001 for all three comparisons).
Conclusions: Among patients undergoing ASCT, 9% develop sup-
raventricular arrhythmias. The risk is elevated among the older pa-
tients, those with a prior history of arrhythmias, and those with
AV conduction delay or premature supraventricular complexes on
ECG. Identification of patients at a higher risk may allow develop-
ment of specific interventions.ALLOGENEIC TRANSPLANTS15
B CELLS FROM PATIENTS WITH CHRONIC GVHD SIGNAL VIA THE AKT-
DRIVEN SURVIVAL AND METABOLIC FITNESS PATHWAY
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Hoffert, T.6, Richards, K.7, Shea, T.C.3, Baldwin, A.S.1, Serody, J.1,3,
Sarantopoulos, S.1,3 1University of North Carolina, Chapel Hill, NC;
2Cambridge Health Alliance, Boston, MA; 3UNC School of Medicine,
Chapel Hill, NC; 4UNC School of Medicine, Chapel Hill, NC; 5UNC
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Allogeneic hematopoietic stemcell transplant patients (HSCT)who
develop chronic GVHD (cGVHD) have delayed B cell reconstitution
S208 Oral Presentationsdespite persistently elevated plasma BAFF levels. High BAFF to B cell
ratios are associatedwith increased proportions of activated peripheral
B cells. B cell reconstitution occurs during constant exposure to allo-
and neo-autoantigens after HSCT. We hypothesize that failure to
delete these potentially pathologic cells in cGVHDisdue toBAFFsig-
naling. We recently found that B cells from patients with active
cGVHD have decreased pro-apoptotic Bim (Wooten et al ASH
2010, Abstract 216). BAFF is known to enhance B cell survival by
counteracting pro-apoptotic Bim, but upstream BAFF-driven survival
signaling in cGVHD (and other diseases) remains undetermined.
HSCT patients who were .12 months post-HSCT, not receiving
high dose steroid, with or without active cGVHD were studied. We
first examined apoptotic rates by flow cytometric analysis of 14 freshly
isolated (to .95% CD19+ purity) B cell samples cultured over time.
Patients with active cGVHD (n 5 4) had significantly decreased
apoptosis at 48 hours, compared to either patients who had never de-
velopeddisease (n55)or tohealthy controls (n5 5) (p\0.005).While
BAFF-driven B cell survival can bemodulated by altered expression of
apoptotic factors, it can also be affected by cellular metabolic fitness.
To examine B cell metabolic fitness wemeasured cellular protein con-
tent in freshly purified B cells from 28 HSCT patients. Significantly
increased B cell protein content was found in active cGVHD patients
(n 5 10) compared to patients who never developed disease (n 5 7)
(p\0.005). Increased protein content was also found in patients who
had inactive disease (n 5 11) although this did not reach statistical
significance. Since BAFF is known to induce metabolic fitness via
phosphorylation of AKT in murine B cells, we examined AKT
activation by immunoblotting freshly isolated B cell lysates from 18
HSCT patients. B cells from patients with active cGVHD (n 5 8)
had significantly increased phosphorylated AKT (pS743 normalized
to total AKT) compared to patients with inactive disease (n 5 7)
(p\0.005). By contrast, no difference in Erk phosphorylation was
found between groups. Our study reveals that B cells in cGVHD
have increased survival due to increased AKT pathway driven
metabolic fitness. Thus, we provide rationale for study of small
molecule inhibitors of the AKT pathway in cGVHD patients.
Table. B cells from patients with cGVHD have increased cel-
lular protein content and AKTactivation
Cellular Protein Normalized One-waycGVHD
GroupContent (mg protein /
1 x 10^6 cells)
Mean +/- SEOne-way
ANOVA,




InactiveNo 35.4 +/- 5.4, n 5 7 - 0.16 +/- 0.09, n 5 3 NSInactive 56.9 +/- 5.2, n 5 11 NS 0.05 +/- 0.02, n 5 7 -Active 75.8 +/- 9, n 5 10 p < 0.005 0.63 +/- 0.15, n 5 8 p < 0.005NS; Not significant.16
PHASE II PILOT STUDYOF IMATINIBMESYLATE FOR THE TREATMENT OF
SEVERE SCLEROTIC SKIN CHRONIC GRAFT VERSUS HOST DISEASE
(ScGVHD)
Baird, K.1, Booher, S.2, Comis, L.E.3, Joe, G.O.3, Steinberg, S.M.5,
Spencer, S.D.6, Figg, W.D.6, Takebe, N.7, Pavletic, S.Z.4,
Cowen, E.W.2 1NIH; 2NIH; 3NIH; 4NIH; 5NIH; 6NIH; 7National In-
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Background: ScGVHD is characterized by progressive fibrosis of
the dermis and subcutis and develops in 4-13% of patients with
cGVHD. The clinical risk factors and mechanisms responsible for
ScGVHD remain unclear; however, the profibrogenic platelet-
derived growth factor (PDGF) and transforming growth factor-
b (TGF-b) signaling pathways have been implicated. Imatinib
mesylate is a tyrosine kinase inhibitor that has activity against both
PDGFR and TGF-b as well as a well-established safety profile for
the treatment of chronic myelogenous leukemia.
Methods: Eligible patients had ScGVHD limiting range-of-motion
(ROM) of at least 1 joint by .25%. Initially, patients were given
400mg (pediatric 260mg/m2) imatinib daily (cohort 1), with dose
reduction allowed for toxicity. Due to a high incidence of adverseeffects (AEs) and subsequent dose reduction, the study was amended
to start 100mg with escalation to 200mg daily at 1 month. The 6
month primary endpoint was based on percent improvement of the
deficit compared to baseline at 1-3 target joints: partial response
(PR) 5 increase of .25%; progressive disease (PD) 5 decrease of
.25%, or .1 steroid pulse per 3-month period; stable disease
(SD) 5 all other. Secondary endpoints included toxicity; multi-mo-
dality skin assessments (MRI, skin score, and patient-reported mea-
sures); quality of life and functional measures; steady state serum
drug concentrations (cohort 2); and response of other cGVHD-af-
fected organs.
Results: Twenty patients were enrolled (8 cohort 1, 12 cohort 2).
Two patients had PD; 5 PR; 7 SD; and 6 were non-evaluable
(Table 1). Of 11/14 (78.6%) patients with any ROM improvement,
the average gain in ROMwas 31%. No significant improvement was
seen in other cGVHD manifestations. Frequent AEs included hy-
pophosphatemia, GI upset, fatigue, muscle cramping and pain.
Other clinically significant AEs were tinnitus (n5 4) and pulmonary
edema requiring hospitalization (n 5 2). Steady state serum con-
centrations in cohort 2 (200mg daily) ranged from 592-2255ng/mL
(mean 1157ng/mL), which is within the inhibitory range of imatinib
on PDGFR.
Table 1. Patient Responses
% changePatient






at 6 mos Response Final Dose1 56 Male 48.5 37% Off-withdrawal N/A N/A2 60 Male 48.2 56% 94% PR 300mg3 10 Female 39.1 73% Off- 3 mos PD PD N/A4 52 Female 28.9 7% Off- toxicity N/A N/A5 30 Male 87.0 34% Off - withdrawal N/A N/A6 51 Male 88.1 47% Off - withdrawal N/A N/A7 55 Female 42.5 61% 35% PR 200 mg8 58 Male 39.1 35% 16% SD 200 mg9 60 Male 79.4 42% Off - withdrawal N/A N/A10 53 Male 20.3 -7% 21% SD 200 mg11 28 Female 15.8 56% Off - cancer
relapse
N/A N/A12 56 Male 80.3 37% 16% SD 100 mg13 34 Female 21.4 27% 61% PR 200 mg14 46 Male 40.6 32% 27% PR 200 mg15 55 Male 33.5 22% 22% SD 200 mg16 55 Male 4.8 71% 3% SD 200 mg17 7 Female 25.4 64% -25% SD 100 mg (peds)18 21 Male 58.9 54% -2% SD 200 mg19 48 Male 112.9 33% 31% PR 200 mg20 18 Male 35.0 -5% 15% SD 200 mgcGVHD 5 chronic graft versus host disease, Dx 5 diagnosis, mo 5
month, ROM5 range of motion, PD5 progressive disease, PR5 partial
response, SD 5 stable disease, N/A 5 not assessed.
Conclusions:Treatment with imatinib mesylate for 6 months led to
improved ROM in most patients. This data suggests that low-dose
imatinib therapy has efficacy for ScGVHD; however, despite serum
drug concentrations in the expected range for the doses prescribed,
tolerability was a significant limitation for the use of imatinib mesy-
late in patients with ScGVHD.
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TARGETED JANUS KINASE-2 INHIBITION OVERCOMES LIMITATIONS OF
IL6-RECEPTOR-ALPHA BLOCKADE IN CONTROLLING HUMAN DC-STIMU-
LATED ALLOREACTIVITY
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Graft-versus-host disease (GvHD) is a serious challenge to the
success of hematopoietic stem cell transplantation. The cytokine
